Viewray (NASDAQ:VRAY) received a $13.00 target price from analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday. The brokerage currently has a “buy” rating on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 37.28% from the company’s current price.
Several other research analysts have also commented on the company. ValuEngine lowered Viewray from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. BidaskClub lowered Viewray from a “buy” rating to a “hold” rating in a research report on Saturday, December 9th. Mizuho reissued a “buy” rating and issued a $12.00 price target on shares of Viewray in a research report on Monday, November 13th. Finally, Northland Securities reissued a “buy” rating and issued a $10.00 price target on shares of Viewray in a research report on Friday, November 17th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $11.20.
Viewray (VRAY) traded up $0.05 on Monday, hitting $9.47. The stock had a trading volume of 1,496,200 shares, compared to its average volume of 777,725. The company has a market cap of $639.64, a price-to-earnings ratio of -8.69 and a beta of 17.60. The company has a current ratio of 1.59, a quick ratio of 1.20 and a debt-to-equity ratio of -1.67. Viewray has a 52-week low of $3.01 and a 52-week high of $10.39.
Viewray (NASDAQ:VRAY) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.07). The firm had revenue of $12.20 million during the quarter, compared to analysts’ expectations of $18.63 million. Viewray’s revenue for the quarter was up 2950.0% compared to the same quarter last year. research analysts forecast that Viewray will post -0.93 earnings per share for the current fiscal year.
Large investors have recently made changes to their positions in the stock. Nationwide Fund Advisors increased its position in Viewray by 843.2% during the 2nd quarter. Nationwide Fund Advisors now owns 16,543 shares of the company’s stock valued at $107,000 after buying an additional 14,789 shares in the last quarter. HighTower Advisors LLC increased its position in Viewray by 5.0% during the 2nd quarter. HighTower Advisors LLC now owns 21,000 shares of the company’s stock valued at $135,000 after buying an additional 1,000 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in Viewray during the 2nd quarter valued at about $159,000. Thompson Siegel & Walmsley LLC acquired a new position in Viewray during the 3rd quarter valued at about $164,000. Finally, White Pine Capital LLC acquired a new position in Viewray during the 2nd quarter valued at about $173,000. 50.02% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This report was first reported by Equities Focus and is the sole property of of Equities Focus. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.equitiesfocus.com/2018/01/08/viewray-vray-given-a-13-00-price-target-by-cantor-fitzgerald-analysts.html.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.